Kornimate/medical-research-clean huggingface dataset:
adherence to treatment in egyptian patients with knee osteoarthritis

Conditions: Knee Osteoarthritis

Summary: the aim is to measure the level of adherence of knee osteoartheritis patients to a carefully curated program that follows the american college of rheumatology/arthritis (acr) recommendation guidelines and investigate the factor that might affect the patient's adherence to the prescribed protocol.

2.3. interventional protocol (for intervention group only): for the intervention group: a face-to-face semi-structured interview was carried out with each participant separately. the interview (30-45minuts) included a health education program explaining the nature of the condition(koa causes, pathological changes, and natural course of the disease), we explained the recommendations for the treatment of koa, teaching the patient a home exercise program of 5 exercises (targeting knee extensor and hip muscle ), selection of a physiotherapy program suitable to the patient clinical condition, recommendations to increase daily physical activity ( e.g. brisk walking) with joint protection measures along with a weight reduction regimen proposed in overweight and obese patients and prescribing a suitable pharmacological treatment to the patients mentioning side effect that might occur. at the end of the interview, each participant received a booklet including the recommendations for the treatment of knee osteoarthritis according to the acr. as for the control group, they were assigned the traditional approach for koa management, they were told their diagnosis if they were not already familiar with it, received the treatment for koa according to acr guidelines, they were offered physical therapy modalities if their condition required but they were not given the health education program or the other interventional steps. 2.4. follow-up period: throughout the following three months after enrollment, participants were followed up every ten days; asking about persistence on the prescribed treatment and exercise program, the level of their daily activity, and their diet plan. for participants who failed to attend for any reason, a telephone call was performed to provide behavior change support in both groups. the telephone call aimed to observe adherence to treatment in the control group and to increase levels of participation in the intervention group.

Eligibility criteria:
inclusion criteria: * diagnosed as having knee osteoarthritis according to the american college of rheumatology criteria exclusion criteria: * patients with a 1. a history of knee trauma or injury 2. patients suffering from any other rheumatological diseases (e.g., rheumatoid arthritis) 3. severe comorbidities, severe cardiovascular disease, heart failure, gastrointestinal bleeding risk, and chronic kidney disease.

Keywords: osteoarthritis knee adherence patient education guidelines
what factors area associated with prognosis after steroid hydrodilatation for adhesive capsulitis

Conditions: Adhesive Capsulitis

Summary: to investigate the factors associated with improvement after intraarticular steroid injection for patients with frozen shoulder

objective: to investigate the factors associated with improvement after intraarticular steroid injection for patients with frozen shoulder design: prospective study. participants: patients with frozen shoulder were recorded the demographic data, associated disease, ultrasound findings at baselines. intervention: one shot intraarticular steroid hydrodilatation main outcome measures: visual analog scale (vas) of the shoulder pain, constant score, spadi score, and angles of active and passive shoulder range of motion (flexion, abduction, external rotation, and internal rotation) at pre-treatment, post-treatment at week 8

Eligibility criteria:
inclusion criteria: * diagnosis of frozen shoulder by physical examination and ultrasonography exclusion criteria: 1. other conditions involving the shoulder ( rheumatoid arthritis, hill-sachs lesions,osteoporosis, or malignancies in the shoulder region); 2. neurologic deficits affecting shoulder function in normal daily activities; 3. shoulder pain caused by cervical radiculopathy 4. a history of drug allergy to xylocaine 5. pregnancy or lactation; 6. received injection into the affected shoulder during the preceding 3 months

Keywords: adhesive capsulitis
randomized controlled trial of acupuncture for dysmenorrhea

Conditions: Dysmenorrhea

Summary: since there is unsatisfactory effect by currently pharmacologic therapies and preventive strategies for dysmenorrhea, this study is designed to evaluate the efficacy and quality of life of acupuncture for patients with dysmenorrhea based on the theory of traditional chinese medicine.

there were abundant clinical experiences and medical records for dysmenorrhea in traditional chinese medicine. so we follow the worldly trend to do the research of integrative chinese medicine and western medicine since who launched the first global strategy on traditional and complementary/alternative medicine (tm/cam) to assist countries to create a stronger evidence base on the safety, efficacy and quality of the tm/cam products and practices. the purpose of our study is to create the evidence of effect on dysmenorrhea by acupuncture. the study will be performed under randomized, open, controlled design. the effect of acupuncture and control group will be compared including the following outcomes: pain score (visual analogue scale), quality of life (sf-36, taiwan version), overall improvement in dysmenorrhea, adverse effects from treatment, requirements for additional medication, restriction of daily life activities, absence from work or school.

Eligibility criteria:
inclusion criteria: * non-pregnant women who are at least 13 years old * the one who meet any one of the following two criteria: 1.suffering from dysmenorrhea in recent 3 menstrual periods; 2.dysmenorrhea with poor response to non-steroid anti-inflammation drugs exclusion criteria: * intrauterine device-related dysmenorrhea * history of alcohol or drug abuser * women who are pregnant, as determined by a urine pregnancy test * history of adverse reaction to acupuncture * received herb or acupuncture therapy within one month prior to enrollment * poor compliance to investigator's advice

Keywords: dysmenorrhea acupuncture randomized controlled trial
staccato granisetron® (az 010) for the treatment of cyclic vomiting syndrome

Conditions: Cyclic Vomiting Syndrome

Summary: this is a multicenter, randomized, double-blind, parallel group, placebo-controlled, efficacy and safety study of adult outpatients diagnosed with cvs and experiencing recurring episodes of stereotypical vomiting.

a randomized, double-blind, placebo controlled study to evaluate the safety and efficacy of staccato granisetron (az-010) for the acute treatment of moderate to severe cyclic vomiting syndrome

Eligibility criteria:
inclusion criteria: * adult males and females between 18 and 60 years of age, inclusive at the time of signing the informed consent document. * diagnosis of cyclic vomiting syndrome (cvs) using the rome iv diagnostic criteria. * otherwise healthy, as determined by the responsible physician, based on a medical evaluation including history, physical examination, vital signs, electrocardiograms (ecgs) and laboratory tests assessed at the screening visit * negative urine tests for selected drugs of abuse and alcohol breath test at screening. exclusion criteria: * any significant medical or psychiatric condition that could, in the investigator's opinion, compromise the subject's safety or interfere with the completion of this protocol. * any condition, including the presence of laboratory abnormalities or pulmonary condition, which according to the investigator places the subject at unacceptable risk if he/she were to participate in the study. * a diagnosis of any gastrointestinal disorder other than cvs that in the judgement of the investigator could compromise the subject's safety or interfere with the interpretation of safety or efficacy data.

Keywords: cyclic vomiting syndrome cvs vomiting retching abdominal migraine nausea stomach pain unexplained vomiting functional gi disorder cvshope.com throwing up puking dry heaving food poisoning episodes repeated food poisoning
pilot trial of her-2/neu pulsed dc1 vaccine for patients with her-2 positive metastatic cancer

Conditions: Metastatic Cancer

Summary: immune-based therapies (vaccines) are a new focus of clinical investigation. these therapies try to assist a patient's immune system (a system in our bodies that protects us against infection) in killing tumors. one form of such therapy is the dendritic cell combined with her-2/neu (a type of protein over-expressed in some cancers) vaccine. dendritic cells are immune cells that can tell your immune system to fight infection. in laboratory testing, these cells may also help the immune system attack tumors such as breast, kidney cancer or skin cancer. the purpose of this research study is to determine if it is both possible and safe to administer" this vaccine to patients with any her2+ cancer.

we have demonstrated that administration of her-2/neu pulsed dc1 in patients with dcis results in strong immunologic responses as well as clinical responses during a brief 4 or 6 week neoadjuvant vaccination. in subsets of patients with cancer her-2 is over-expressed including subsets of breast, gastric, pancreatic, brain, lung, and colon cancer. this trial is designed for compassionate use of a her-2/neu pulsed dc1 in patients with metastatic her-2 positive cancer, who have no longer standard options to eliminate disease.

Eligibility criteria:
inclusion criteria: 1. age ≥ 18 years. 2. subjects with active metastatic her-2 positive cancer, at least 1+ by ihc, that have already received standard therapy who have exhausted other treatment options. 3. subjects with her-2 1+ need to be hla 2 or hla a3 positive. there are no hla restrictions for her-2 2+ or 3+. 4. women of childbearing age with a negative pregnancy test documented prior to enrollment. 5. subjects with ecog performance status score of 0 or 1 (appendix d). 6. women of childbearing potential must agree to use a medically acceptable form of birth control (medically accepted methods: birth control pills, condoms and spermicidal lubricants, intrauterine device, and diaphragm) during their participation in the study. 7. subjects who have voluntarily signed a written informed consent in accordance with institutional policies after its contents have been fully explained to them. - exclusion criteria: 1. pregnant or lactating females. 2. subjects with positive hiv or hepatitis c at baseline by self report. 3. subjects with coagulopathies, including thrombocytopenia with platelet count \ 1.5 and partial thromboplastin time \> 50 sec 4. subjects with major cardiac illness muga or echo \< 50% ef. 5. subjects with pre-existing medical illnesses or medications which might interfere with the study as determined by pi. 6. subjects receiving current therapy that may suppress immune system, such as steroids, chemotherapy at the discretion of the pi.
intra- and inter-evaluator reproducibility of upper limb strength measures in patients with copd

Conditions: Chronic Obstructive Pulmonary Disease

Summary: according to the recommendations of french and international learned societies, respiratory rehabilitation is part of the care of patients with chronic obstructive pulmonary disease (copd). indeed, scientific work carried out for more than 10 years on the respiratory rehabilitation of patients suffering from copd shows that respiratory rehabilitation allows a reduction of the handicap caused by the disease and an improvement in the quality of life of the patients. a respiratory rehabilitation program (prr) includes: individual exercise re-training, therapeutic education, respiratory physiotherapy, help with smoking cessation and nutritional and psychosocial care. exercise retraining includes training the muscles of the lower limbs in endurance and strength combined with training the muscles of the upper limbs. strengthening the upper limbs helps reduce dyspnea in patients with copd. in order to determine a precise muscle building protocol, it is necessary to assess at the start of the program the maximum voluntary strength (fmv) of the different muscle groups of the upper limbs. measuring fmv quantifies a possible frequent strength deficit in patients with copd and the effects of the strengthening program. currently, tests to assess fmv using isokinetic dynamometers are used as a benchmark. however, this material is little used in current practice. portable dynamometers are used to perform simple tests and to obtain muscle strength measurements. however, the reliability of the maximum voluntary force measurements of the different muscle groups of the upper limb has not been evaluated. studies seem necessary to determine the reproducibility of the measurement in intra and inter-examiner (schrama 2014) and to assess its sensitivity to change during a respiratory rehabilitation program. the objectives of this study are to study the reproducibility, validity and sensitivity to change of the measurement of fmv using a portable dynamometer.


Eligibility criteria:
inclusion criteria: * patient with copd stages 2 to 4 (a to d) admitted to the pulmonary rehabilitation unit of centre hospitalier des pays de morlaix (4 weeks) * patient able to consent and having signed a consent form * patient 18 years of age or older exclusion criteria: * patient with pain, arthritis, prosthetics, shoulder or elbow surgery. * patient with a history of pneumonectomy, lobectomy less than 6 months old * refusal to participate * patient with an inability to follow a full respiratory rehabilitation program * patient under guardianship or curatorship
investigation of optimal dosing conditions for a long acting glp-1 analogue in healthy male subjects

Conditions: Diabetes; Diabetes Mellitus, Type 2; Healthy

Summary: this trial is conducted in europe. the aim of the trial is to evaluate the optimal dosing conditions for semaglutide (a long acting glp-1 analogue) in healthy male subjects.


Eligibility criteria:
inclusion criteria: * good general health as judged by the investigator, based on medical history, physical examination, electrocardiogram (ecg), vital signs and clinical laboratory * body mass index (bmi) of 18.5-30.0 kg/m\^2 (both inclusive) exclusion criteria: * males who are sexually active and not surgically sterilised, who or whose partner(s): a. are not using adequate contraceptive methods (e.g. condom with spermicidal foam/gel/film/cream or contraceptives with a pearl index below 1%, such as implants, injectables, combined oral contraceptives, or hormonal intrauterine devices or diaphragm + spermicide) or b. do not refrain from sexual intercourse during the trial and until 30 days following the last dose of trial medication. in addition, subjects must not donate sperm for the duration of the trial and for 30 days following the last dose of trial medication or c. sterilization of either partner * suffer from a life threatening disease or has a history of any clinically significant disease or disorder * history of acute idiopathic or chronic pancreatitis * calcitonin value equal to or above 50 ng/l * any clinically significant abnormal laboratory test results (haematology, biochemistry and urinalysis), as judged by the investigator and any of the following laboratory safety results (based on screening results): amylase, lipase and creatinine, above upper normal range. aspartate aminotransferase (asat), alanine aminotransferase (alat) and gamma-glutamyl-transpeptidase (gamma-gt) above 1.5 times upper normal range (unr). thrombocytes below 0.75 times lower normal range (lnr) or above 1.25 times unr. leucocytes outside 3.0 to 11.0x10\^9/l (normal range is 3.91 to 8.77x10\^9/l. sodium outside the range 130.0 to 150.0 mmol/l (normal range is 136-145 mmol/l). potassium outside the range 3.0 to 5.5 mmol/l (normal range is 3.5 to 5.1 mmol/l) * any clinically significant abnormal ecg, as judged by the investigator * subjects who are smokers
midodrine use in septic shock

Conditions: Septic Shock

Summary: the investigators aim to perform a randomized, double-blind, placebo-controlled trial to investigate the efficacy of midodrine in decreasing time to iv vasopressor liberation in patients with septic shock.

a growing body of literature comprising largely retrospective data seems to support the safety and efficacy of midodrine in the intensive care unit for decreasing iv vasopressor use. the investigators hypothesize that administration of midodrine in the early phase of septic shock in patients with adequate enteral access will result in a significant decrease in time to iv vasopressor liberation (increase in vasopressor-free days), secondarily resulting in decreased central venous catheter dwell times and intensive care unit length of stay.

Eligibility criteria:
inclusion criteria: * patients aged ≥18-89 years old * admitted to uva medical icu with diagnosis of septic shock. * patients requiring at least 5 mcg/min norepinephrine infusion (or equivalent) for blood pressure support for at least 3 hours * patients with enteral access established within 12 hours of admission (either able to swallow, or feeding tube in place) exclusion criteria: * pregnant females; (due to the potential adverse effects to an unborn child); patients with childbearing potential will have results of pregnancy test checked (which is routinely performed on admission); should the patient have child-bearing potential and the pregnancy status is not checked as part of routine care, such patients will be excluded from the study (i.e. pregnancy testing will not be performed for research purposes) * patients \< 18 years * prisoners * patients already taking midodrine * patients with cirrhosis of the liver as defined by either biopsy, imaging findings of cirrhosis and thrombocytopenia or patients otherwise undergoing liver transplant evaluation * patients with increased intraocular pressure and glaucoma * patients with allergy to midodrine * non-english speaking patients, due to the narrow time-frame for study enrollment and execution of study protocol, employing interpreters is deemed to be a significant burden on the investigators with potential to hamper study enrollment. non-english speaking patients are not deemed to be adversely affected by exclusion from study as there is no clear a priori reason why study results would not also apply to non-english speakers. * patients without enteral access within 12 hours of initiation of iv vasopressors * patients where the attending physician does not clinically intend to target a mean arterial pressure of \> 65 mmhg * patients with pheochromocytoma or thyrotoxicosis * patients with active bowel ischemia
cone beam vs mdct for diagnosis and pre-operative evaluation of otosclerosis

Conditions: Otosclerosis

Summary: this study aims to compare the cone beam and the multi-detector computed tomography for diagnosis and pre-operative evaluation of otosclerosis in patients addressed for conductive hearing loss with intact tympanic membrane. the study aims to show that the cone beam offers equivalent performances with lower radiation dosage in this indication

otosclerosis is an inflammatory bone remodeling disorder of the otic capsule, characterized by spongiotic new bone formation, causing stamped ankylosis that can result in conductive hearing loss. until now, the gold standard imaging technique for diagnosis and pre-operative evaluation of otosclerosis has been multi-detector computed tomography (mdct). cone beam computed tomography is a relatively recent imaging modality. it is associated with a lower radiation dosage compared to mdct, and a high spatial resolution that allows a more precise analysis of bone structures. during the last 15 years, its use has been increasingly common in odontology and craniofacial surgery. several studies have already studied the utility of cone beam for temporal bone pathologies, including recent retrospective studies that showed satisfying diagnostic performances for otosclerosis. up to now, very few prospective studies have compared those two imaging modalities for otosclerosis diagnosis and pre-operative evaluation. therefore, those two exams will be performed in patients addressed to the hospital for conductive hearing loss with intact tympanic membrane. thus, the performance of cone beam will be compared to mdct, regarding the positive diagnosis of otosclerosis, the analysis of anatomical structures of the temporal bone for pre-operative evaluation, and also the benefits in terms of irradiation. the mdcts will include fewer slices than routine mdcts and will be centered on the area of interest, in order to keep a total radiation dosage smaller or equivalent to routine care

Eligibility criteria:
inclusion criteria: * adult patients (18 years and older) * requiring radiological assessment for conductive hearing loss with intact tympanic membrane, confirmed by otoscopy and audiogram * signed informed consent * affiliated or beneficiary of health insurance exclusion criteria: * absence of otosclerosis on the mdct * history of middle ear surgery * pregnancy, breast feeding women and women who are of childbearing age and not practicing adequate birth control * patient under legal protection

Keywords: otosclerosis cone beam conductive hearing loss
exercise intensity and type 2 diabetics

Conditions: Type 2 Diabetes

Summary: the purpose of this study is to determine if a single session of aerobic exercise effectively controls the blood pressure (bp) of individuals with type 2 diabetes mellitus (t2dm) over the 24h of post-exercise period, and the effects of intensity of aerobic exercise on these bp responses.


Eligibility criteria:
inclusion criteria: * sedentary * a diagnosis of t2dm for at least one year * glycemic control through nutrition and/or medication exclusion criteria: * be not under use of exogenous insulin and do not present chronic complications such as diabetic foot * nephropathy * retinopathy * neuropathies and cardiovascular diseases

Keywords: aerobic exercise blood pressure